blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4094774

EP4094774 - USE OF INTERFERON IN PREPARING DRUG FOR PREVENTING CORONAVIRUS INFECTION OR PREVENTING DISEASE CAUSED BY CORONAVIRUS INFECTION [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  23.06.2023
Database last updated on 02.11.2024
FormerRequest for examination was made
Status updated on  28.10.2022
FormerThe international publication has been made
Status updated on  27.08.2021
Most recent event   Tooltip26.10.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Shanghai Ganyi Medical Biotechnology Inc.
Unit 201, Second Floor, Building 4
No. 588 Qing Dai Road
No. 208 Ban Xia Road
Pudong New District
Shanghai 200120 / CN
For all designated states
Meng, Zhongji
No. 10 Beijing South Road
Maojian District Shiyan
Hubei 442012 / CN
For all designated states
Ll, Hai
No. 2-203, Lane 50, Binyang Road
Xuhui District
Shanghai 200035 / CN
[2022/48]
Inventor(s)01 / MENG, Zhongji
No. 10 Beijing South Road,
Maojian District Shiyan
Hubei 442012 / CN
02 / LI, Hai
No. 2-203, Lane 50, Binyang Road,
Xuhui District
Shanghai 200035 / CN
 [2022/48]
Representative(s)De Clercq & Partners
Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem / BE
[2022/48]
Application number, filing date21757541.419.02.2021
[2022/48]
WO2021CN76904
Priority number, dateCN20201010808521.02.2020         Original published format: CN202010108085
CN20201037859407.05.2020         Original published format: CN202010378594
[2022/48]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021164740
Date:26.08.2021
Language:ZH
[2021/34]
Type: A1 Application with search report 
No.:EP4094774
Date:30.11.2022
Language:EN
[2022/48]
Search report(s)International search report - published on:CN26.08.2021
(Supplementary) European search report - dispatched on:EP02.06.2023
ClassificationIPC:A61K38/21, A61P31/12, A61P31/16, A61P11/00, A61P31/14
[2023/27]
CPC:
A61K38/21 (EP); A61K38/212 (EP,CN,US); A61K38/215 (EP,CN,US);
A61K38/217 (EP,CN,US); A61K9/0043 (EP,US); A61K9/0073 (US);
A61P11/00 (EP,CN); A61P31/14 (EP,CN,US) (-)
Former IPC [2022/48]A61K38/21, A61P31/12, A61P31/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/48]
TitleGerman:VERWENDUNG VON INTERFERON ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR VORBEUGUNG VON CORONAVIRUS-INFEKTIONEN ODER ZUR VORBEUGUNG VON DURCH CORONAVIRUS-INFEKTIONEN VERURSACHTEN KRANKHEITEN[2022/48]
English:USE OF INTERFERON IN PREPARING DRUG FOR PREVENTING CORONAVIRUS INFECTION OR PREVENTING DISEASE CAUSED BY CORONAVIRUS INFECTION[2022/48]
French:UTILISATION D'INTERFÉRON DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LA PRÉVENTION D'UNE INFECTION À CORONAVIRUS OU LA PRÉVENTION D'UNE MALADIE PROVOQUÉE PAR UNE INFECTION À CORONAVIRUS[2022/48]
Entry into regional phase25.08.2022Translation filed 
25.08.2022National basic fee paid 
25.08.2022Search fee paid 
25.08.2022Designation fee(s) paid 
25.08.2022Examination fee paid 
Examination procedure25.08.2022Amendment by applicant (claims and/or description)
25.08.2022Examination requested  [2022/48]
02.06.2023Date on which the examining division has become responsible
26.06.2023Despatch of a communication from the examining division (Time limit: M04)
03.11.2023Reply to a communication from the examining division
19.02.2024Despatch of a communication from the examining division (Time limit: M04)
18.06.2024Reply to a communication from the examining division
27.06.2024Despatch of a communication from the examining division (Time limit: M04)
25.10.2024Reply to a communication from the examining division
Fees paidRenewal fee
27.02.2023Renewal fee patent year 03
28.02.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]CN1535724  (BEIJING JINDIKE BIOLOG TECHNOL [CN]);
 [X]US2005002901  (BLATT LAWRENCE M [US]);
 [XI]CN1777438  (SCICLONE PHARMACEUTICALS INC [US]);
 [XP]CN111671886  (SHANGHAI GANYI BIOMEDICAL TECH CO LTD, et al);
International search[A]WO2010120511  (ALTAIR THERAPEUTICS INC [US], et al) [A] 1-14* see entire document *;
 [X]CN1927389B  (BEIJING JINDIKE BIOTECHNOLOGY RES INST, et al) [X] 2, 5-9, 11-13 * see the abstract, and claim 1 *;
 [X]  - Kunling Shen et al., "Diagnosis, Treatment, and Prevention of 2019 Novel Coronavirus Infection in Children: Experts’ Consensus Statement", World Journal of Pediatrics, (20200207), vol. 16, no. 3, doi:10.1007/s12519-020-00343-7, XP037176937 [X] 1-14 * pp. 223-231, see page 226, left column, the last paragraph to right column, paragraph 1 *

DOI:   http://dx.doi.org/10.1007/s12519-020-00343-7
 [X]  - YU, Dexian et al., "A Field Trial of Recombinant Human Interferon α-2b for Nasal Spray to Prevent SARS and Other Respiratory Viral Infections", Chinese Journal of Experimental and Clinical Virology, (20050930), vol. 19, no. 3, pages 216 - 219, XP055840338 [X] 2, 5-9, 11-13 * pages 216-219, see page 218, left column, paragraph 2 *
ExaminationCN102416166
 CN102716105
 CN102727469
 CN103690934
 CN105920586
by applicant   - "Epidemiology group of emergency response mechanism for novel coronavirus pneumonia, Chinese Center for Disease Control and Prevention. Analysis of Epidemiological characteristics of novel coronavirus pneumonia [J", Chinese Journal of Epidemiology, (20200000), vol. 41, no. 2, pages 145 - 151
    - EDWARD LKAREN B, "Coronavirus Disease 2019 (COVID-19) in Italy[J", JAMA, (20200000), vol. 323, no. 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.